Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
LOTZ Carlotz Inc
TSLA Tesla Inc
INN Summit Hotel Properties Inc
NCNO nCino Inc
FISK Empire State Realty OP LP
RMD Resmed Inc
BST BlackRock Science and Technology Trust
MPW Medical Properties Trust Inc
UWHR Uwharrie Capital Corp
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Closing Price
$605.25
Day's Change
2.06 (0.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
618.01
Day's Low
600.27
Volume
(Average)
Volume:
857,852

10-day average volume:
847,815
857,852

REGN's position in the Biotechnology industry

Industry PeersREGNAMGNGILDINCYUTHR

Summary

Company ProfileRegeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Go to AMGN summary
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer...
Go to GILD summary
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development...
Go to INCY summary
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and...
Go to UTHR summary
52-Week Change

VS. INDUSTRY
11.24%
-13.94%
0.96%
-26.03%
20.45%
Market Cap

VS. INDUSTRY
$65.1B
$125.3B
$84.5B
$16.2B
$8.9B
Beta

VS. INDUSTRY
0.2
0.6
0.4
0.7
0.6
Dividend Yield

VS. INDUSTRY
--
3.49%
4.22%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
9.66x
22.92x
11.53x
30.44x
20.13x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$13.5B
$25.8B
$27.5B
$2.9B
$1.7B
Profit Margin

VS. INDUSTRY
51.65%
21.77%
26.81%
18.35%
27.94%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
40.78%
6.33%
-61.76%
--
-1.93%
Revenue Growth (TTM)

VS. INDUSTRY
64.28%
3.12%
18.73%
18.58%
17.43%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.